PD-1 blockade in renal cell carcinoma: to equilibrium and beyond

Lauren C. Harshman, Charles G. Drake, Toni K. Choueiri

Research output: Contribution to journalReview article

Abstract

The past several years have witnessed a resurgence of interest in cancer immunotherapy. The development of blocking antibodies against the inhibitory programmed death-1 (PD-1) pathway represents a clinical breakthrough in the treatment of solid tumors such as melanoma, and these agents show great promise in renal cell carcinoma (RCC). The early data have been surprising in that they demonstrate that blockade of a single immune checkpoint can elicit objective responses in patients with RCC, despite the recognized complexity of the immunosuppressive tumor microenvironment. Reinvigorating the patient's own immune cells to reactivate and to target the tumor has the potential advantages of more selective killing and thus decreased toxicity. In addition, checkpoint blockade immunotherapy has the advantage of inducing a memory response that is unattainable with our current cytotoxic and targeted therapies. This Crossroads overview will highlight the emerging investigation of PD-1 blockade in RCC and how this T cell-targeted strategy may thwart the tumor's escape mechanisms and shift the immune system/tumor balance back to a state of equilibrium and even to tumor elimination.

Original languageEnglish (US)
Pages (from-to)1132-1141
Number of pages10
JournalCancer immunology research
Volume2
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Renal Cell Carcinoma
Neoplasms
Immunotherapy
Tumor Escape
Blocking Antibodies
Tumor Microenvironment
Immunosuppressive Agents
Immune System
Melanoma
T-Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

PD-1 blockade in renal cell carcinoma : to equilibrium and beyond. / Harshman, Lauren C.; Drake, Charles G.; Choueiri, Toni K.

In: Cancer immunology research, Vol. 2, No. 12, 01.12.2014, p. 1132-1141.

Research output: Contribution to journalReview article

Harshman, Lauren C. ; Drake, Charles G. ; Choueiri, Toni K. / PD-1 blockade in renal cell carcinoma : to equilibrium and beyond. In: Cancer immunology research. 2014 ; Vol. 2, No. 12. pp. 1132-1141.
@article{f4865e584ff949b4a2c037b2a25ec4b0,
title = "PD-1 blockade in renal cell carcinoma: to equilibrium and beyond",
abstract = "The past several years have witnessed a resurgence of interest in cancer immunotherapy. The development of blocking antibodies against the inhibitory programmed death-1 (PD-1) pathway represents a clinical breakthrough in the treatment of solid tumors such as melanoma, and these agents show great promise in renal cell carcinoma (RCC). The early data have been surprising in that they demonstrate that blockade of a single immune checkpoint can elicit objective responses in patients with RCC, despite the recognized complexity of the immunosuppressive tumor microenvironment. Reinvigorating the patient's own immune cells to reactivate and to target the tumor has the potential advantages of more selective killing and thus decreased toxicity. In addition, checkpoint blockade immunotherapy has the advantage of inducing a memory response that is unattainable with our current cytotoxic and targeted therapies. This Crossroads overview will highlight the emerging investigation of PD-1 blockade in RCC and how this T cell-targeted strategy may thwart the tumor's escape mechanisms and shift the immune system/tumor balance back to a state of equilibrium and even to tumor elimination.",
author = "Harshman, {Lauren C.} and Drake, {Charles G.} and Choueiri, {Toni K.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1158/2326-6066.CIR-14-0193",
language = "English (US)",
volume = "2",
pages = "1132--1141",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - PD-1 blockade in renal cell carcinoma

T2 - to equilibrium and beyond

AU - Harshman, Lauren C.

AU - Drake, Charles G.

AU - Choueiri, Toni K.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - The past several years have witnessed a resurgence of interest in cancer immunotherapy. The development of blocking antibodies against the inhibitory programmed death-1 (PD-1) pathway represents a clinical breakthrough in the treatment of solid tumors such as melanoma, and these agents show great promise in renal cell carcinoma (RCC). The early data have been surprising in that they demonstrate that blockade of a single immune checkpoint can elicit objective responses in patients with RCC, despite the recognized complexity of the immunosuppressive tumor microenvironment. Reinvigorating the patient's own immune cells to reactivate and to target the tumor has the potential advantages of more selective killing and thus decreased toxicity. In addition, checkpoint blockade immunotherapy has the advantage of inducing a memory response that is unattainable with our current cytotoxic and targeted therapies. This Crossroads overview will highlight the emerging investigation of PD-1 blockade in RCC and how this T cell-targeted strategy may thwart the tumor's escape mechanisms and shift the immune system/tumor balance back to a state of equilibrium and even to tumor elimination.

AB - The past several years have witnessed a resurgence of interest in cancer immunotherapy. The development of blocking antibodies against the inhibitory programmed death-1 (PD-1) pathway represents a clinical breakthrough in the treatment of solid tumors such as melanoma, and these agents show great promise in renal cell carcinoma (RCC). The early data have been surprising in that they demonstrate that blockade of a single immune checkpoint can elicit objective responses in patients with RCC, despite the recognized complexity of the immunosuppressive tumor microenvironment. Reinvigorating the patient's own immune cells to reactivate and to target the tumor has the potential advantages of more selective killing and thus decreased toxicity. In addition, checkpoint blockade immunotherapy has the advantage of inducing a memory response that is unattainable with our current cytotoxic and targeted therapies. This Crossroads overview will highlight the emerging investigation of PD-1 blockade in RCC and how this T cell-targeted strategy may thwart the tumor's escape mechanisms and shift the immune system/tumor balance back to a state of equilibrium and even to tumor elimination.

UR - http://www.scopus.com/inward/record.url?scp=84979860405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979860405&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-14-0193

DO - 10.1158/2326-6066.CIR-14-0193

M3 - Review article

C2 - 25480555

AN - SCOPUS:84979860405

VL - 2

SP - 1132

EP - 1141

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 12

ER -